Biopharmaceutics modelling of extended-release formulations with sequential TIM-1/TIM-2 biorelevant upper GI and colonic dissolution
Journal of Controlled Release · 2026-12 · 400 · 115461
DOI: 10.1016/j.jconrel.2026.115461 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-12. Verfasst von Connor O'Farrell und 4 weiteren Autor:innen. Beteiligte Einrichtung: InnoGI Technologies, Thijsseweg 11, Delft, 2629 JA, The Netherlands. Electronic address: connor.ofarrell@innogitechnologies.com. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Predicting the in vivo performance of extended-release (ER) products is difficult because drug release is excipient-controlled and may continue into the colon, a region poorly represented by conventional dissolution methods. Here, a biorelevant in vitro-in silico workflow was established to support formulation development of ER rocavorexant, a BCS II compound formulated as a HPMC-matrix tablet. Formulations were screened for food effect risk using the dynamic in vitro TIM-1 gastrointestinal model, before dissolution profiles measured during sequential TIM-1/TIM-2 upper-GI and colonic transit were used as a dissolution input for a physiologically-based biopharmaceutics model (PBBM) of oral rocavorexant administration. TIM dissolution profiles were constructed from intraluminal samples taken from the gastric, duodenal, jejunal, ileal and colonic compartments and from filtrate/dialysate samples of the jejunal, ileal and colonic compartments. PBBM simulations driven by conventional USP-I dissolution, either as a direct input or following level A IVIVC transformation, did not adequately reproduce clinical pharmacokinetics, underpredicting early exposure and missing key features of the plasma concentration-time profile. Sequential TIM-1/TIM-2 input predicted clinical exposure well (predicted/observed Cmax 1.03; AUC 0.91-0.94), recovered the key features of the profile and facilitated mechanistic insights to link regional release, solubilisation, absorption and pharmacokinetics.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- InnoGI Technologies, Thijsseweg 11, Delft, 2629 JA, The Netherlands. Electronic address: connor.ofarrell@innogitechnologies.com.
- InnoGI Technologies, Thijsseweg 11, Delft, 2629 JA, The Netherlands.
- Indivior, Inc., 2579 Midpoint Drive, Ft. Collins, CO, USA.
Zitieren
APA
O'Farrell, C., Chatterjee, M., van den Elsen, L. W. J., Garcia, T. M., & Barnhill, D. (2026). Biopharmaceutics modelling of extended-release formulations with sequential TIM-1/TIM-2 biorelevant upper GI and colonic dissolution. Journal of Controlled Release, 400, 115461. https://doi.org/10.1016/j.jconrel.2026.115461
Vancouver
O'Farrell C, Chatterjee M, van den Elsen LWJ, Garcia TM, Barnhill D. Biopharmaceutics modelling of extended-release formulations with sequential TIM-1/TIM-2 biorelevant upper GI and colonic dissolution. Journal of Controlled Release. 2026;400:115461. doi:10.1016/j.jconrel.2026.115461
BibTeX
@article{OFarrell2026,
author = {O'Farrell, Connor and Chatterjee, Maitrayee and van den Elsen, Lieke W J and Garcia, Tânia Martins and Barnhill, Dan},
title = {Biopharmaceutics modelling of extended-release formulations with sequential TIM-1/TIM-2 biorelevant upper GI and colonic dissolution},
journal = {Journal of Controlled Release},
year = {2026},
volume = {400},
pages = {115461},
doi = {10.1016/j.jconrel.2026.115461}
}
EUVIMED